| Id: | acc3165 |
| Group: | 2sens |
| Protein: | AMPK |
| Gene Symbol: | PRKAA2 |
| Protein Id: | P54646 |
| Protein Name: | AAPK2_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr172 |
| Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
| Disease Category: | Cell stress and damage |
| Disease: | Apoptosis |
| Disease Subtype: | |
| Disease Cellline: | HUVEC |
| Disease Info: | |
| Drug: | adiponectin |
| Drug Info: | Adiponectin is a protein hormone primarily secreted by adipose tissue. It plays a crucial role in regulating energy homeostasis and glucose and lipid metabolism. |
| Effect: | modulate |
| Effect Info: | Adiponectin blocks palmitate-induced endothelial cell apoptosis by activating the AMPK (Thr-172 phosphorylation) and cAMP/PKA pathways and inhibiting ROS production. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 20675307 |
| Sentence Index: | 20675307_4-5 |
| Sentence: | "The AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR; 1 mM), and cAMP activators forskolin (10 muM) and cholera toxin (200 ng/ml) also displayed the same effects. The inhibitory effects of adiponectin on ROS generation and apoptosis were reversed by the AMPK inhibitor compound C (40 muM), cAMP inhibitor SQ22536 (50 muM), and protein kinase A (PKA) inhibitor H-89 (10 muM)." |
Sequence & Structure:
MAEKQKHDGRVKIGHYVLGDTLGVGTFGKVKIGEHQLTGHKVAVKILNRQKIRSLDVVGKIKREIQNLKLFRHPHIIKLYQVISTPTDFFMVMEYVSGGELFDYICKHGRVEEMEARRLFQQILSAVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSCGVILYALLCGTLPFDDEHVPTLFKKIRGGVFYIPEYLNRSVATLLMHMLQVDPLKRATIKDIREHEWFKQDLPSYLFPEDPSYDANVIDDEAVKEVCEKFECTESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQASEFYLASSPPSGSFMDDSAMHIPPGLKPHPERMPPLIADSPKARCPLDALNTTKPKSLAVKKAKWHLGIRSQSKPYDIMAEVYRAMKQLDFEWKVVNAYHLRVRRKNPVTGNYVKMSLQLYLVDNRSYLLDFKSIDDEVVEQRSGSSTPQRSCSAAGLHRPRSSFDSTTAESHSLSGSLTGSLTGSTLSSVSPRLGSHTMDFFEMCASLITTLAR
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| PRKAA2 | ACADESINE | AMP-activated protein kinase, AMPK activator | 3 | - | cardiovascular disease | ATC |
| PRKAA2 | ACADESINE | AMP-activated protein kinase, AMPK activator | 1 | Completed | chronic lymphocytic leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| PRKAA2-Thr172 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | 0.934 |
| HGSC | -1.055 |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | 0.121 |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
